Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hidroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresivi - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Europska Unija - hrvatski - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Europska Unija - hrvatski - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - kolitis, ulcerativni - imunosupresivi - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - ibuprofenum, pseudoephedrinum - filmom obložena tableta - 200 mg + 30 mg - urbroj: jedna filmom obložena tableta sadrži 200 mg ibuprofena i 30 mg pseudoefedrinklorida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

messer croatia plin d.o.o., industrijska 1, zaprešić - dušikov (ii) oksid - medicinski plin, stlačen - 800 ppm (v/v) - urbroj: spremnik za plin od 2 litre napunjen pri apsolutnom tlaku od 200 bara sadrži 381 litru plina pod tlakom od 1 bara pri 15 °c; spremnik za plin od 10 litara napunjen pri apsolutnom tlaku od 200 bara sadrži 1903 litre plina pod tlakom od 1 bara pri 15 °c; spremnik za plin od 20 litara napunjen pri apsolutnom tlaku od 200 bara sadrži 3806 litara plina pod tlakom od 1 bara pri 15 °c

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

servier pharma d.o.o., tuškanova 37, zagreb - perindoprilum, indapamidum, amlodipinum - filmom obložena tableta - 2,5 mg + 0,625 mg + 5 mg - urbroj: jedna filmom obložena tableta sadrži 1,6975 mg perindoprila što odgovara 2,5 mg perindoprilarginina, 0,625 mg indapamida i 6,935 mg amlodipinbesilata što odgovara 5 mg amlodipina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

apc instytut sp. z o.o., ul. aleje jerozolimskie 146c, varšava, mazowieckei, poljska - rivaroksaban - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 15 mg rivaroksabana

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

apc instytut sp. z o.o., ul. aleje jerozolimskie 146c, varšava, mazowieckei, poljska - rivaroksaban - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 20 mg rivaroksabana